ROSELLA – GOG-3073 – ENGOT-OV72/MITO: A phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer (1241)
Year: 2023
Type: article
Source: Gynecologic Oncology
Authors: Alexander Olawaiye, Toon Van Gorp, Bradley Monk, Zoltan Novak, David O'Malley, Ana Oaknin, Thomas Herzog, Laurence Gladieff, Edwin Alvarez, Jacob Korach, John Chan, Shibani Nicum, Erin Bishop, Anita Chudecka-Glaz, Allan Covens, Carolyn Muller, Gina Westhoff, David Fishman, Lyndah Dreiling, Hristina Pashova, Iulia Cristina Tudor, Domenica Lorusso
Institutions: University of Pittsburgh, Magee-Womens Hospital, KU Leuven, Creighton University, University of Arizona, HonorHealth, National Institute of Oncology, The Ohio State University, Vall d'Hebron Hospital Universitari, Spanish Ovarian Cancer Research Group, Vall d'Hebron Institute of Oncology, University of Cincinnati, Institut Claudius Regaud, University of California, San Francisco, Sheba Medical Center, California Pacific Medical Center, University College London, National Cancer Research Institute, Medical College of Wisconsin, Pomeranian Medical University, Sunnybrook Health Science Centre, University of Toronto, UNM Comprehensive Cancer Center, Cornell University, Corcept Therapeutics (United States), Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4386954022